Economics of Innovation
Optimal innovation balances willingness and ability to pay with the benefits of future R&D. Our wide-ranging programme aims to promote innovation in health care, increase our understanding of its value, and encourage R&D. New models of innovation should streamline development, reduce costs, and speed patient benefit.
Does Government Funding Increase Public Sector Development of New Medicines?
5 March 2021
Looking at public sector drug development in Europe, this paper suggests that government funding does have an impact on the research and development pipeline, particularly at the earlier stages of research for medicines targeting rare diseases.
It Takes Two to Tango: When do Conditional Reimbursement Risk-Sharing Schemes Work for Both Parties?
1 December 2021
Faster regulatory approval has not necessarily achieved faster patient access. A new OHE paper sets out how risk-sharing can tackle this, enabling resolution of differences of…
Payment Models for Multi-Indication Therapies
1 November 2021
For the growing number of multi-indication medicines, access may be delayed or even denied due to challenges in linking payment with a medicine’s value across those…
Working Towards a Sustainable, Healthy Market for Vaccines: a Comprehensive Framework to Support Policy Dialogue and Decision-Making
1 September 2021
By placing a strain on health care systems and the global economy, the COVID-19 pandemic clearly shows the need to more comprehensively understand both supply- and…
The Lower Drug Costs Now Act and Pharmaceutical Innovation
1 September 2021
The US spends significantly more on healthcare per person than other wealthy countries. H.R. 3 is a recent policy proposal aimed at reducing national spending on…
Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Cancer Treatments
8 January 2021
Histology independent therapies are changing the picture of cancer treatment and in so doing don’t ‘fit the frame’ of value assessment. What are the key challenges on the pathway from regulatory to Health Technology Assessment and how can we bridge those? This blog summarises expert and audience insights from an OHE-led ISPOR Educational Session, held Nov 9th 2020.
Key Considerations for Early Access Schemes for Single-Administration (One-Time) Therapies
1 June 2021
Early access schemes enable patients in exceptional need to access therapies that are not yet available through their health system. These schemes were not designed for…
Exploring the Financial Sustainability of Gene Therapies
5 January 2021
Gene therapies represent a paradigm shift in medicine, with the potential to address the root causes of chronic diseases. They offer one-time treatment regimens and, in some cases, potentially a cure. As a result, they offer transformative value for patients, physicians, health systems and society. However, with the prospect of more gene therapy approvals there is concern in Europe that these technologies could threaten the financial sustainability of health systems.
The Promise of Gene Therapies: Are We Ready?
1 April 2021
In a webinar held on 16 March 2021, Mary Harney, Annie Hubert and Simone Boselli joined OHE’s Adrian Towse to debate the issues surrounding the adoption of gene therapies. In this interactive report we highlight our 5 key takeaways from the debate with clips, quotes and highlights.